Lugui Qiu
邱录贵
Chief Physician; Clinical Chief Expert; Tenured Associate Professor; Doctoral Supervisor
Multiple myeloma, B-cell lymphoma, chronic lymphocytic leukemia, adult acute lymphoblastic leukemia, and CAR-T or other translational immunotherapies for plasma-cell and lymphoid malignancies.(多发性骨髓瘤、B细胞淋巴瘤、慢性淋巴细胞白血病、成人急性淋巴细胞白血病，以及面向浆细胞和淋巴系统恶性肿瘤的CAR-T等转化免疫治疗。)
Pioneering Contributions
Built one of China’s leading lymphoma and myeloma clinical-translational programs at the Institute of Hematology CAMS, with official profiles crediting him for establishing advanced diagnostic and treatment systems that improved outcomes.
Leadership & Positions
- Committee Member, International Myeloma Society (IMS)
- Committee Member, International Myeloma Working Group (IMWG)
- Chairman, Myeloma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Honorary Chairman, Hematology Oncology Committee, China Anti-Cancer Association
- Vice Chairman, Chinese Hospital Association Hematology Branch
Medical School
Jiangxi Medical College (1985)
Graduate
MS in Hematology, Peking Union Medical College and Chinese Academy of Medical Sciences
Fellowships & Training
University of Louisville — Research associate training in hematology/oncology (United States)
Languages
Notable Publications
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial.
JAMA Oncology (2024) — corresponding author
PubMed/DOIA phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Blood (2021) — co-author
PubMed/DOIDevelopment and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
American Journal of Hematology (2024) — co-author
PubMed/DOIIdentification of a CAR-Derived Clone by NGS-Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma.
American Journal of Hematology (2025) — co-author
PubMed/DOIPioneering Contributions
- Built one of China’s leading lymphoma and myeloma clinical-translational programs at the Institute of Hematology CAMS, with official profiles crediting him for establishing advanced diagnostic and treatment systems that improved outcomes.
- Led the multicenter FUMANBA-1 study of fully human BCMA CAR-T therapy (eque-cel) in relapsed/refractory multiple myeloma, a landmark China-led registration-relevant trial reported by the hospital and JAMA Oncology.
- Helped drive Chinese guideline and consensus development in myeloma through roles in IMS, IMWG, and CSCO, including high-level work on CAR-T response assessment and management.
- Official profiles credit his team with helping move at least 8 to 10 lymphoma and myeloma drugs from clinical trials toward market approval in China.
Active Clinical Trials
Equecabtagene autoleucel in relapsed or refractory multiple myeloma
FUMANBA-1 — Phase Phase 1b/2 (JAMA Oncology publication and official hospital report)
Sources — Lugui Qiu
- https://www.chinablood.com.cn/jyb/department_navigation/lblzlzx/doctor/818.html—official Chinese identity verification, current hospital affiliation, clinic schedule, specialty description, hospital profile URL(accessed Apr 16, 2026)
- https://www.chinablood.com.cn/en/science/team/10200.html—official English name, department framing, education and career chronology, myeloma/CAR-T research profile, leadership roles(accessed Apr 16, 2026)
- https://yzbss.pumc.edu.cn/basicinfo/tutorinfo/tutordetail/J2009140182—PUMC tutor profile verification of title, chief-expert status, PI role, awards, publication volume, and disease focus(accessed Apr 16, 2026)
- https://www.chinablood.com.cn/zyb/science/dynamic/10094.html—official hospital report confirming Qiu Lugui led the phase 1b/2 FUMANBA-1 eque-cel study in relapsed/refractory multiple myeloma and reporting enrolled cohort details(accessed Apr 16, 2026)
- https://www.chinablood.com.cn/zyb/science/dynamic/10758.html—official hospital report on Qiu Lugui team’s BCMA CAR-T and NGS-MRD publication, supporting CAR-T relevance(accessed Apr 16, 2026)
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39509090&...—PubMed verification for FUMANBA-1 JAMA Oncology publication(accessed Apr 16, 2026)
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=33512480&...—PubMed verification for CT103A Blood publication(accessed Apr 16, 2026)
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38247315&...—PubMed verification for MPSS multiple myeloma publication(accessed Apr 16, 2026)
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40446088&...—PubMed verification for AJH BCMA CAR-T MRD publication(accessed Apr 16, 2026)